ISLET AMYLOID POLYPEPTIDE - DOES IT PLAY A PATHOPHYSIOLOGICAL ROLE IN THE DEVELOPMENT OF DIABETES

被引：9

作者：

BENNETT, WM ^{[1
]}

SMITH, DM ^{[1
]}

BLOOM, SR ^{[1
]}

机构：

[1] HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,DU CANE RD,LONDON W12 0NN,ENGLAND

来源：

DIABETIC MEDICINE | 1994年 / 11卷 / 09期

关键词：

ISLET AMYLOID POLYPEPTIDE; TYPE; 2; DIABETES; PATHOGENESIS; PANCREAS;

D O I：

10.1111/j.1464-5491.1994.tb00363.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

There is suggestive evidence that amylin acts physiologically in an autocrine manner within the islet to restrain insulin secretion, but conversely there is little indication that this action of amylin plays any role in the development of NIDDM. Deposition of amylin within pancreatic islets is a feature in patients with NIDDM but is of sufficient degree to disrupt beta-cell function in only a small minority of individuals. Current evidence suggests that amylin does not have any physiologically important extra-islet metabolic effects. The potential exists for the development of amylin antagonists as pharmacological agents to enhance insulin secretion in NIDDM but antagonism of systemic CGRP would need to be avoided. There is little, if any, indication that either replacement of amylin or treatment with amylin agonists are likely to have any beneficial role in patients with IDDM.

引用

页码：825 / 829

页数：5

共 61 条

[31] Gedulin B., Cooper GJS, Young AA, Amylin secretion from the perfused pancreas: Dissociation from insulin and abnormal elevation in insulin‐resistant diabetic rats, Biochem Biophys Res Commun, 180, pp. 782-789, (1991)
[32] Bhogal R., Smith DM, Bloom SR, Investigation and characterization of binding sites for islet amyloid polypeptide in rat membranes, Endocrinology, 130, pp. 906-913, (1992)
[33] Stridsberg M., Tjalve H., Wilander E., Whole‐body autoradiography of <sup>123</sup>I‐labelled islet amyloid polypeptide (IAPP), Acta Oncol, 32, pp. 155-159, (1993)
[34] Barakat A., Marie JC, Rosselin G., Le recepteur du peptide apparente au gene de la calcitonine (CGRP) est present sur les membranes des insulinomes, C R Acad Sci III, 310, pp. 189-194, (1990)
[35] Beaumont K., Kennedy MA, Young AA, Rink TJ, High affinity amylin binding sites in rat brain, Mol Pharmacol, 44, pp. 493-497, (1993)
[36] Dennis T., Fournier A., Guard S., Pierre S., Quirion R., Calcitonin gene‐related peptide (hCGRPα) binding sites in the nucleus accumbens. Atypical structural requirements and marked phylogenic differences, Brain Res, 539, pp. 59-66, (1991)
[37] Wahlestedt C., Pich EM, Koob GF, Yee F., Heilig M., Modulation of anxiety and neuropeptide Y‐Y1 receptors by antisense oligodeoxynucleotides, Science, 259, pp. 528-531, (1993)
[38] Fried M., Schwizer W., Beglinger C., Keller U., Jansen JB, Lamers CB, Physiological role of cholecystokinin on postprandial insulin secretion and gastric emptying in man. Studies with the cholecystokinin receptor antagonist loxiglumide, Diabetologia, 34, pp. 721-726, (1991)
[39] Wang ZL, Bennet WM, Ghatei MA, Byfield PG, Smith DM, Bloom SR, Influence of islet amyloid polypeptide and the 8–37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets, Diabetes, 42, pp. 330-335, (1993)
[40] Bhogal R., Smith DM, Purkiss P., Bloom SR, Molecular identification of binding site for calcitonin gene‐related peptide (CGRP) and islet amyloid polypeptide (IAPP) in mammalian lung: Species variation and binding of truncated CGRP and IAPP, Endocrinology, 133, pp. 2351-2361, (1993)

← 1 2 3 4 5 6 7 →